Description

HBT1 – Product Information

• HBT1 is offered as a 1g powder.

What is HBT1?

Hbt1 is known to have a Molecular Weight of 386.39 with IUPAC name of 2-[[2-[4-(ethylaminomethyl)-3-(trifluoromethyl)pyrazol-1-yl]acetyl]amino]-4,5,6,7-tetrahydro-1-benzothiophene-3-carboxamide. It’s an AMPA receptor potentiator that causes the production of brain-derived neurotrophic factor (BDNF) and has little agonistic effect on primary neurons.

Other synonym for HBT1 is 2-[({4-[(Ethylamino)methyl]-3-(Trifluoromethyl)-1h-Pyrazol-1-Yl}acetyl)amino]-4,5,6,7-Tetrahydro-1-Benzothiophene-3-Carboxamide

The protein known as a brain-derived neurotrophic factor (BDNF) induces the production of positive results as it plays a significant part in the maintenance and expansion of neurons, acts as a neurotransmitter modulator, and contributes to the neuronal plasticity that is intended for learning and memory.

Neurodegenerative illnesses characterized by neuronal death, such as Parkinson’s disease, Alzheimer’s disease, multiple sclerosis, and Huntington’s disease, have been linked to lower levels of the neurotrophic factor BDNF.

Therefore, an increase in BDNF may prove to be helpful in the treatment as well as the prevention of a number of disorders.

How Does HBT1 Work?

HBT1 binds to the ligand-binding domain of α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor (AMPA-R) in glutamate-dependent manner.

This means that HBT1 is a molecule that can bind to a specific site of the AMPA-R protein only when there is glutamate present, and this binding helps regulate the activity of the protein.

AMPA receptors are expressed throughout the CNS and play essential roles in neuronal communication, sensory processing, as well as learning, memory, and synaptic plasticity.[R]

AMPA receptors are the primary contributors of excitatory neurotransmission, mediating the quick, rapidly desensitizing excitement of numerous synapses, and are engaged in the early response to glutamate in the synaptic region. Their activation allows sodium to enter the neuronal membrane by opening the channel’s pore, which depolarizes the membrane.

This alteration in intracellular charge dislodges the Mg2+ cation from the N-methyl-D-aspartate (NMDA) receptor channel, allowing Ca2+ to flow through the pore. The AMPA receptors consist of a homomeric or heteromeric four-subunit complex (GluR1-4).

Through impacts on desensitization time and receptor trafficking, differences in subunit expression, posttranscriptional modifications, and alternative splicing modifications confer a wide range of functional diversity and complexity to these types of receptors.

AMPA receptors are typically co-expressed with NMDA receptors in synapses, where they jointly contribute to synaptic plasticity processes involved in learning, memory, excitotoxicity, and neuroprotection. [R]

HBT1 Research

Numerous animal and human studies have been conducted on the potential application of HBT1. This page follows some of the relevant findings:

HBT1 on Brain-derived Neurotrophic Factor (BDNF)

Brain-Derived Neurotrophic Factor (BDNF) is a neurotrophin with potent and many effects on the proliferation, differentiation, survival, and death of neuronal and non-neuronal cells, making it crucial for the health and well-being of the nervous system.

HBT1 is a new AMPA receptor potentiator with reduced agonistic effect in primary neurons and the absence of a bell-shaped response in vitro BDNF synthesis.[R]

HBT1 on Neurological Diseases

It was mentioned above that HBT1 helps increase BDNF. This increase in BDNF suggests that exogenously administered BDNF can prevent neuronal loss, and diminish nigral neuron susceptibility to glutamate inputs, and thus may be of benefit in Huntington’s and Parkinson’s diseases. [R]

BDNF stimulates and controls the process of Neurogenesis. Also, it stimulates and controls this process. BDNF protein and mRNA have been found in most parts of the brain, including the olfactory bulb, cortex, hippocampus, basal forebrain, mesencephalon, hypothalamus, brainstem, and spinal cord.

Many neurodegenerative diseases, such as Parkinson’s disease (PD), multiple sclerosis (MS), and Huntington’s disease, cause BDNF levels to go down.

BDNF does more than just protect neurons; it also helps keep energy levels stable. When BDNF is given outside of the brain or into the brain (intracerebroventricularly, or ICV), it stops the body from eating and makes it lose weight.

A large quantity of investigation is required to determine the role of HBT1 in affecting BDNF production.